Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition - PubMed (original) (raw)
Review
. 2017 Apr;18(3):162-214.
doi: 10.1080/15622975.2016.1190867. Epub 2016 Jul 15.
David Baldwin 2, Marianna Abelli 3, Blanca Bolea-Alamanac 4, Michel Bourin 5, Samuel R Chamberlain 6 7, Eduardo Cinosi 8, Simon Davies 9 4, Katharina Domschke 10, Naomi Fineberg 6, Edna Grünblatt 10 11 12 13, Marek Jarema 14, Yong-Ku Kim 15, Eduard Maron 16 17 18, Vasileios Masdrakis 19, Olya Mikova 20, David Nutt 18, Stefano Pallanti 21, Stefano Pini 3, Andreas Ströhle 22, Florence Thibaut 23, Matilde M Vaghi 24, Eunsoo Won 15, Dirk Wedekind 1, Adam Wichniak 14, Jade Woolley 2, Peter Zwanzger 25 26, Peter Riederer 10
Affiliations
- PMID: 27419272
- PMCID: PMC5341771
- DOI: 10.1080/15622975.2016.1190867
Review
Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition
Borwin Bandelow et al. World J Biol Psychiatry. 2017 Apr.
Abstract
Objective: Biomarkers are defined as anatomical, biochemical or physiological traits that are specific to certain disorders or syndromes. The objective of this paper is to summarise the current knowledge of biomarkers for anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD).
Methods: Findings in biomarker research were reviewed by a task force of international experts in the field, consisting of members of the World Federation of Societies for Biological Psychiatry Task Force on Biological Markers and of the European College of Neuropsychopharmacology Anxiety Disorders Research Network.
Results: The present article (Part II) summarises findings on potential biomarkers in neurochemistry (neurotransmitters such as serotonin, norepinephrine, dopamine or GABA, neuropeptides such as cholecystokinin, neurokinins, atrial natriuretic peptide, or oxytocin, the HPA axis, neurotrophic factors such as NGF and BDNF, immunology and CO2 hypersensitivity), neurophysiology (EEG, heart rate variability) and neurocognition. The accompanying paper (Part I) focuses on neuroimaging and genetics.
Conclusions: Although at present, none of the putative biomarkers is sufficient and specific as a diagnostic tool, an abundance of high quality research has accumulated that should improve our understanding of the neurobiological causes of anxiety disorders, OCD and PTSD.
Keywords: Anxiety disorders; genetic; neurobiology; neurochemistry; neuroimaging; review.
Conflict of interest statement
All other authors reported no conflicts of interest to declare.
Figures
Figure 1
GABA-A receptor and subunit structure; GABA and benzodiazepine (BZD) binding site (Domschke & Zwanzger 2008).
Figure 2
Stress-induced interactions between nervous, endocrine and immune systems. The hypothalamus secretes CRH in response to stress, and from the paraventricular nucleus of the hypothalamus. CRH-containing neurons have projections to the locus coeruleus. The locus coeruleus sends direct projections to the sympathetic and parasympathetic preganglionic neurons, increasing sympathetic activity and decreasing parasympathetic activity through the activation of adrenoceptors. In turn, the activation of the sympathetic nervous system stimulates the release of CRH. The products of sympathetic and parasympathetic nervous system activity are NE and E, and ACh, respectively. When stress is prolonged, as in anxiety disorders, the sympathetic nervous system continues to be activated with a lack of parasympathetic counteractivity. As a result, NE and E levels are increased and ACh levels are decreased, which leads to an increased release of pro-inflammatory cytokines from immune cells. Pro-inflammatory cytokines such as TNF, IL1 and IL6 then trigger the activation of the sympathetic nervous system. CRH, corticotropin-releasing hormone; NE, norepinephrine; E, epinephrine; ACh, acetylcholine, TNF, tumour necrosis factor; IL1, interleukin-1; IL6, interleukin-6; +, stimulation; −, inhibition.
Similar articles
- Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics.
Bandelow B, Baldwin D, Abelli M, Altamura C, Dell'Osso B, Domschke K, Fineberg NA, Grünblatt E, Jarema M, Maron E, Nutt D, Pini S, Vaghi MM, Wichniak A, Zai G, Riederer P. Bandelow B, et al. World J Biol Psychiatry. 2016 Aug;17(5):321-65. doi: 10.1080/15622975.2016.1181783. Epub 2016 Jul 12. World J Biol Psychiatry. 2016. PMID: 27403679 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD.
Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller HJ, Eriksson E, Fineberg NA, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman MA, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Nardi AE, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J. Bandelow B, et al. World J Biol Psychiatry. 2023 Feb;24(2):118-134. doi: 10.1080/15622975.2022.2086296. Epub 2022 Jul 28. World J Biol Psychiatry. 2023. PMID: 35900217 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders; Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. Bandelow B, et al. World J Biol Psychiatry. 2008;9(4):248-312. doi: 10.1080/15622970802465807. World J Biol Psychiatry. 2008. PMID: 18949648 - [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G, Naja WJ, Pelissolo A. Ammar G, et al. Encephale. 2015 Jun;41(3):260-5. doi: 10.1016/j.encep.2013.11.002. Epub 2014 Nov 14. Encephale. 2015. PMID: 25439852 Review. French. - Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Bandelow B, et al. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. doi: 10.3109/13651501.2012.667114. Epub 2012 Apr 30. Int J Psychiatry Clin Pract. 2012. PMID: 22540422
Cited by
- A multiscale inflammatory map: linking individual stress to societal dysfunction.
Vodovotz Y, Arciero J, Verschure PF, Katz DL. Vodovotz Y, et al. Front Sci. 2024;1:1239462. doi: 10.3389/fsci.2023.1239462. Epub 2024 Mar 11. Front Sci. 2024. PMID: 39398282 Free PMC article. - Late-onset major depressive disorder: exploring the therapeutic potential of enhancing cerebral brain-derived neurotrophic factor expression through targeted microRNA delivery.
Lai G, Malavolta M, Marcozzi S, Bigossi G, Giuliani ME, Casoli T, Balietti M. Lai G, et al. Transl Psychiatry. 2024 Sep 3;14(1):352. doi: 10.1038/s41398-024-02935-7. Transl Psychiatry. 2024. PMID: 39227372 Free PMC article. Review. - Regional brain activity and connectivity associated with childhood trauma in drug-naive patients with obsessive-compulsive disorder.
Zhang M, Wu C, Lu S, Wang Y, Ma R, Du Y, Wang S, Fang J. Zhang M, et al. Sci Rep. 2024 Aug 5;14(1):18111. doi: 10.1038/s41598-024-69122-y. Sci Rep. 2024. PMID: 39103500 Free PMC article. - COVID-19 and Mental Health: A "Pandemic Within a Pandemic".
Fisicaro F, Lanza G, Concerto C, Rodolico A, Di Napoli M, Mansueto G, Cortese K, Mogavero MP, Ferri R, Bella R, Pennisi M. Fisicaro F, et al. Adv Exp Med Biol. 2024;1458:1-18. doi: 10.1007/978-3-031-61943-4_1. Adv Exp Med Biol. 2024. PMID: 39102186 Review. - Recurrent COVID-19-related psychotic disorder with neuro-immuno-endocrine dysfunction as a possible underlying mechanism: A case report from China.
Yang C, He Y, Yuan L, Yuan C, Chang F, Feng W, Zhou B. Yang C, et al. Brain Behav Immun Health. 2024 Jun 6;39:100803. doi: 10.1016/j.bbih.2024.100803. eCollection 2024 Aug. Brain Behav Immun Health. 2024. PMID: 39022626 Free PMC article.
References
- Abelli M, Chelli B, Costa B, Lari L, Cardini A, Gesi C, Muti M, Lucacchini A, Martini C, Cassano GB, et al. Reductions in platelet 18-kDa translocator protein density are associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology. 2010;62:98–103. - PubMed
- Abelson JL, Curtis GC. Cardiac and neuroendocrine responses to exposure therapy in height phobics: desynchrony within the ‘physiological response system’. Behav Res Ther. 1989;27:561–567. - PubMed
- Abelson JL, Curtis GC, Cameron OG. Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res. 1996;30:79–93. - PubMed
- Abelson JL, Khan S, Liberzon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety. 2007;24:66–76. - PubMed
- Aboitiz F. Dynamics of neuromodulators–I. The role of dopaminergic signaling in goal-directed behavior. In: Aboitiz F, Cosmelli D, editors. From attention to goal-directed behavior. Heidelberg, Berlin: Springer-Verlag; 2009. pp. 187–204.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical